NATCO Pharma Limited (NSE:NATCOPHARM)
India · Delayed Price · Currency is INR | Market Cap | 147.10B +3.2% |
| Revenue (ttm) | 34.85B -20.7% |
| Net Income | 11.44B -32.6% |
| EPS | 63.89 -32.6% |
| Shares Out | 179.11M |
| PE Ratio | 12.85 |
| Forward PE | 18.86 |
| Dividend | 5.00 (0.61%) |
| Ex-Dividend Date | Aug 20, 2026 |
| Volume | 717,250 |
| Open | 814.95 |
| Previous Close | 827.50 |
| Day's Range | 804.00 - 827.10 |
| 52-Week Range | 792.05 - 1,226.80 |
| Beta | 0.16 |
| Analysts | Hold |
| Price Target | 1,004.44 (+22.64%) |
| Est. Earnings | Nov 6, 2026 |
About NATCO Pharma
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain mana... [Read more]
Financial Performance
In fiscal year 2026, NATCO Pharma's revenue was 40.82 billion, a decrease of -7.90% compared to the previous year's 44.32 billion. Earnings were 14.19 billion, a decrease of -24.76%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for NATCOPHARM stock is "Hold." The 12-month stock price target is ₹1,004, which is an increase of 22.64% from the latest price.
News
Natco Pharma to raise ₹1,279 crore via rights issue
Natco Pharma approves ₹1,279.35 crore rights issue at ₹750/share; record date Oct 1, 2026. Issue opens Oct 12, closes Oct 22; ratio 2:21.
Natco’s AP formulations unit gets USFDA Form 483 with 4 observations
Natco Pharma’s Parawada formulations facility received a USFDA Form 483 with four observations after an Aug 17–21, 2026 inspection; company says issues are procedural.
NATCO Pharma Transcript: Q1 26/27
Q1 FY27 saw revenue decline year-over-year due to lower lenalidomide sales, but EBITDA margin improved and normalized PAT grew 34% sequentially. Strong growth in Brazil and a higher stake in Adcock Ingram boosted international performance, while domestic business and Crop Health Sciences are expected to grow further.
NATCO Pharma Quarterly report: Q1 2027
NATCO Pharma has published its Q1 2027 quarterly earnings report on August 14, 2026.
NATCO Pharma Slides: Q1 2027
NATCO Pharma has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 14, 2026.
NATCO Pharma Slides: Investor presentation
NATCO Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
NATCO Pharma approves Rs 1,069 crore investment to raise Adcock Ingram stake to 49%
NATCO Pharma has approved the acquisition of an additional stake in South Africa-based Adcock Ingram Holdings Proprietary Limited, increasing its shareholding from 35.75% to 49%. The transaction, valu...
Pharma sector stocks today, July 8: Natco Pharma falls 1.90%m Zydus Life surge 1.71%, Strides Pharma down 1.33%
Indian pharma sector stocks showed a mixed trend in early trade on July 8, 2026, even as the broader benchmark indices, the S&P BSE Sensex and Nifty 50, traded lower.…
Pharma sector stocks rally today, June 23: IPCA Labs up 2.54%, Dr. Reddys Lab gains 2.47%, Natco Pharma rises 2.45%
Pharma stocks saw strong broad-based gains on June 23, 2026, during the early morning session, with almost all stocks trading in the green. The broader market was largely flat, with…
Pharma sector stocks rises today, June 18: Wockhardt up 2.86%, Natco Pharma gains 2.38%, Panacea Biotech rises 2.01%
Pharma stocks traded broadly in positive territory on June 18, 2026, during the early morning session, with most stocks posting gains. The broader market was largely flat, with the Nifty…
Pharma sector stocks rise today, June 12: Panacea Biotech gains 2.50%, Wockhardt rises 2.24%, Natco Pharma up 1.36%
Pharma stocks traded broadly in positive territory on June 12, 2026, during the early morning session, with most stocks posting gains. The broader market was also strong, with the Nifty…
Pharma sector stocks today, June 5: Panacea Biotech up 6.14%, Wockhardt falls 6.49%, Natco Pharma down 1.79%
Pharma stocks traded mixed on June 5, 2026, during the late morning session, with a majority of stocks posting gains while a handful remained under selling pressure. The broader market…
Pharma sector stocks today, June 4: Panacea Biotech up 7.24%, Wockhardt gains 3.09%, Natco Pharma falls 1.63%
Pharma stocks traded mixed on June 4, 2026, during the early morning session, with several stocks posting gains while others remained under mild selling pressure. The broader market was relatively…
Lupin And Natco Receive FDA Approval For Eribulin Mesylate Injection
(RTTNews) - Lupin Limited (LUPIN) and its alliance partner Natco Pharma Limited announced that the U.S FDA has approved Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection,...
Lupin, Natco Receive FDA Approval For Eribulin Mesylate Injection
(RTTNews) - Lupin (500257, LUPIN) and its alliance partner Natco Pharma announced the approval from the FDA for Natco's Abbreviated New Drug Application for Eribulin Mesylate Injection, 1 mg/2 mL Sing...
Natco Pharma and Lupin secure U.S. FDA approval for Eribulin Mesylate Injection
Natco Pharma Limited and its alliance partner Lupin Limited have received approval from the United States Food and Drug Administration (U.S. FDA) for Natco’s Abbreviated New Drug Application (ANDA) fo...
Pharma sector stocks today, June 3: Natco Pharma falls 2.57%, Zydus Lifesciences falls 1.26%, Alembic Pharma down 1.06%
Pharmaceutical stocks traded mixed on June 3, 2026, during the morning session. While a few stocks posted modest gains, several others witnessed selling pressure. The BSE Healthcare index declined 0.2...
Natco Pharma shares fall 20% since Q4 results announcement; profit drops 34%, revenue declines 39.5%
Shares of Natco Pharma fell sharply on Monday, June 1, after investors reacted to a weak set of Q4FY26 earnings. The stock declined over 6% to Rs 953.30 during the…
Pharma Stocks Today, June 1: Wockhardt surges 12%, Natco Pharma crashes 6%, Glenmark Pharma down 3.63%
Pharmaceutical stocks traded mixed on June 1, 2026, during the early morning session. While a few stocks like Wockhardt and Sudeep Pharma posted strong gains, several others, including Natco Pharma…
NATCO Pharma Transcript: Q4 25/26
FY26 saw a decline in revenue and profit due to lower Revlimid sales and increased competition, with a one-time tax benefit partially offsetting the drop. FY27 guidance is for further contraction, but management expects diversified growth from FY28, driven by new launches and global expansion.
NATCO Pharma Quarterly report: Q4 2026
NATCO Pharma has published its Q4 2026 quarterly earnings report on May 29, 2026.
NATCO Pharma Slides: Q4 2026
NATCO Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 29, 2026.
NATCO Pharma Annual report: Q4 2026
NATCO Pharma has published its Q4 2026 annual report on May 29, 2026.
Top losers today: life insurance corporation at ₹411.35 plunges 50.44%, natco pharma at ₹1,015.90 down 13.60%, jyoti CNC at ₹596.00 falls 9.28%
The Indian stock market witnessed a downturn today, with both the SENSEX and NIFTY 50 indices experiencing declines of 1.44% and 1.50%, respectively. Among the top losers, Life Insurance Corporation…
Pharma sector stocks fall today, May 18: Alembic Pharma crashes 8.32%, Natco Pharma down 2.48%, Aarti Drugs declines 2.27%
Indian pharmaceutical stocks traded mostly lower on May 18 2026 during the morning session. The BSE Healthcare index declined 0.87% to 46,781.22, in line with the broader market weakness. The…